GlaxoSmithKline
G1NYSETrackedHealth CareDiversified
Public exchange feeds are not currently returning active trading data for GlaxoSmithKline (G1). This company may be delisted, bankrupt, acquired, or halted. To preserve data integrity, prices are never displayed as $0.00. Sourced ESG ratings and sustainability disclosures remain cataloged below.
- Coverage
- Coverage universe Identity published; no third-party ESG observation yet.
- ESG profile reviewed
- Last editorial update to this profile.
- Quote
- Market data unavailableObservation time is shown beside the price.
- Methodology
- How we rateProvider ratings are shown separately, never blended.
Market overview
Market data unavailable
Massive Stock Widgets has not returned a current, verifiable snapshot for GlaxoSmithKline (nyse:G1). Check again later.
Company Profile & Business Model Overview
GSK plc is a UK-based global biopharma company focused on vaccines, specialty medicines, and general medicines, with major franchises in HIV, respiratory and immunology, and infectious disease.
Sustainability Strengths & Catalysts (Pros)
- Set one of the most ambitious environmental goals in pharma: net-zero impact on climate and net-positive impact on nature by 2030, including an ~80% absolute emissions cut from a 2020 baseline.
- Embeds access and equity into strategy through its Access to Medicines program, using tiered pricing and voluntary licensing to widen vaccine and essential-medicine availability in low- and middle-income countries.
- Targets 100% renewable electricity, sustainable and deforestation-free sourcing, and an electric sales-fleet transition, and runs a Sustainable Procurement Programme to tackle the ~40% of its footprint sitting in the supply chain.
Material Risks & Governance Concerns (Cons)
- Reaching carbon neutrality by 2030 relies partly on carbon credits to offset the residual ~20% of emissions, exposing it to the broader credibility debate around offsets.
- Roughly 40% of GSK's carbon footprint sits in a complex global supply chain, making Scope 3 reductions dependent on thousands of third-party suppliers and harder to control.
Related ESG Peer Equities
Companies in Health Care evaluated across carbon intensity, social metrics, and board governance.
ESG & Sustainability Rating Breakdown
Synthesized multi-provider rating across Environmental, Social, and Corporate Governance dimensions.
Audited Methodology
Formal published scorecards from MSCI ESG Research and Sustainalytics are not currently available for this ticker. The Impact Investor tracks corporate sustainability disclosures, SEC 10-K filings, and governance releases.
Data integrity and methodology
MSCI and Sustainalytics ratings are shown separately with their own observation dates; they are not blended into one score, and providers can disagree. Market quotes are delayed or last-close values, and every snapshot states its source and observation time. Read the full rating methodology.
Financial & Valuation Fundamentals
Core balance sheet and equity valuation metrics sourced from corporate filings.
Audited Financials
Related ESG Financial Tools & Modeling
ESG Investment Growth Calculator
Project compound future portfolio values versus traditional index benchmarks.
Launch Tool →
Portfolio Carbon Footprint Calculator
Translate your investment capital into financed greenhouse gas emissions.
Launch Tool →
Green Mortgage Calculator
Calculate interest rate discounts on energy-efficient certified homes.
Launch Tool →
Featured Sustainable Investment Research & Guides
Top 12 Impact Investing Apps & Platforms (Reviewed)
Comprehensive review of the best ESG micro-investing and direct indexing apps.
Biblically Responsible Investing (BRI): Top Stocks & Funds
Faith-based screening criteria, ESG alignment, and values-based portfolio strategies.
Top Desalination & Clean Water Infrastructure Stocks
Invest in global clean water purification, reverse osmosis, and municipal utilities.
Best Certified B-Corp Banks & Sustainable Banking
How to align your everyday cash reserves with social and climate impact standards.
Frequently Asked Questions
Direct answers on sustainability scores, risk methodologies, and peer rankings.
What is GlaxoSmithKline (G1)'s ESG rating and sustainability score?
Formal published scorecards from MSCI and Sustainalytics are under ongoing review for GlaxoSmithKline (G1). The Impact Investor tracks corporate sustainability disclosures, SEC 10-K filings, and governance releases.
Is GlaxoSmithKline considered an ESG leader or laggard in Health Care?
Independent benchmark status for GlaxoSmithKline is evaluated relative to Health Care peers once third-party coverage publishes official methodology scores.
What are the main ESG risks and controversies for GlaxoSmithKline?
Key material risks for GlaxoSmithKline include: Reaching carbon neutrality by 2030 relies partly on carbon credits to offset the residual ~20% of emissions, exposing it to the broader credibility debate around offsets.; Roughly 40% of GSK's carbon footprint sits in a complex global supply chain, making Scope 3 reductions dependent on thousands of third-party suppliers and harder to control.. Investors should evaluate whether corporate mitigation plans adequately address these vulnerabilities.
How does The Impact Investor evaluate ESG stock profiles?
The Impact Investor presents audited third-party ratings from MSCI and Sustainalytics alongside delayed market data and financial fundamentals. We do not blend ratings into proprietary black-box scores, and ratings are never modified by advertising or affiliate relationships.